| ||
| Bionomics Limited (ASX:BNO) Open Briefing - CEO on BNC Clinical Trials and ... Finance News Network (press release) The mesothelioma trial is recruiting strongly and will report interim data in the second quarter. BNC105 has been well tolerated by patients in both the ... See all stories on this topic » |
Tip: Use site restrict in your query to search within a site (site:nytimes.com or site:.edu). Learn more.
Remove this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment